The deal gives Lilly control of AtaiBeckley’s lead investigational program, BPL-003, which is being developed as a potential treatment for treatment-resistant depression
We use cookies to personalize content and ads, to provide social media
features and to analyze our traffic. We may also share information about
your use of our site with our social media, advertising and analytics
partners. If you continue to use our site, you consent to our use of
cookies as detailed in our updated
Privacy Policy
.
